News

World's first fast-acting Anti-Rabies drug will be launched in India this year.

Researchers isolate Ebola antibodies in quest for vaccine, treatment.

MassBiologics discovery is nearing launch in India.

Local Delegation tours MassBiologics SouthCoast Facility.

MassBiologics collaborator AbCellera Announces their Success.

Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Td Vaccine in US.

MassBiologics now fully manufacturing vaccine at Mattapan facility.

MassBiologics tests new way to stave off Lyme Disease: Boston Magazine

MassBiologics: Cementing Massachusetts' Status as Life Sciences Hub for over 120 Years

Gene therapy startup Voyager announces manufacturing partnership with MassBiologics

Voyager Therapeutics and MassBiologics Announce Strategic Collaboration for Viral Vector Manufacturing

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab

MassBiologics scientist publishes guide to large scale mammalian cell culture equipment

FDA grants orphan drug status to MassBiologics for MBL-HCV-1

MassBiologics receives UMASS S&T award

MassBiologics receives UMASS President award

MassBiologics Donates Over One Million Doses of Tetanus and Diphtheria Vaccine to Global NGO Project HOPE

MassBiologics CEO, Mark Klempner discusses Lyme disease

Project Hope Update - MassBiologics noted amongst philanthropic donors

Merck study reveals mechanism of action for anti-C.difficile MAb developed at MassBiologics

Mechanism of action and epitopes of the C. difficile toxin B neutralizing antibody bezlotoxumab

Tufts study points to site of action for MassBiologics developed anti-C.difficile antibodies

▴ Back To Top
Section Menu To Top